rs4994 — ADRB3 Trp64Arg

Beta-3 adrenergic receptor variant that impairs catecholamine-stimulated lipolysis and thermogenesis in visceral adipose tissue, increasing susceptibility to abdominal obesity and metabolic dysfunction

See your personal result for ADRB3

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

ADRB3 Trp64Arg — The Fat-Burning Throttle

Deep in your adipose tissue, a molecular switch controls how efficiently your body burns stored fat during periods of catecholamine stimulation — the adrenaline-driven signal that activates lipolysis during fasting, exercise, and cold exposure. The ADRB3 gene encodes the beta-3 adrenergic receptor11 beta-3 adrenergic receptor
A G-protein-coupled receptor expressed predominantly in white and brown adipose tissue; activated by noradrenaline and adrenaline to trigger fat breakdown and heat generation, which plays a central role in thermogenesis22 thermogenesis
The process by which the body generates heat by burning calories, distinct from muscular heat production; especially important in visceral and brown adipose depots and lipolysis33 lipolysis
The enzymatic breakdown of stored triglycerides into free fatty acids and glycerol, releasing energy from fat cells in visceral fat depots.

The Trp64Arg variant (rs4994) replaces tryptophan with arginine at position 64 of the receptor protein, altering the conformation of the first intracellular loop — the structural region that links the receptor to its downstream signaling cascade. Cell studies demonstrate that adipocytes carrying the Arg64 allele generate approximately 70% less cAMP and glycerol44 approximately 70% less cAMP and glycerol
In response to a selective β3 agonist — cAMP is the second messenger that initiates lipolysis; glycerol release measures actual fat breakdown in response to beta-3 stimulation compared to wild-type cells, effectively throttling the fat-burning signal.

This variant was first reported in 1995, simultaneously in three independent papers, including the landmark Walston et al. study in Pima Indians55 Walston et al. study in Pima Indians
Walston J et al. Time of onset of non-insulin-dependent diabetes mellitus and genetic variation in the beta-3-adrenergic-receptor gene. N Engl J Med, 1995 — a population with exceptionally high rates of obesity and diabetes — where homozygous carriers showed earlier onset of type 2 diabetes and a trend toward lower resting metabolic rate. Decades of subsequent research have painted a nuanced picture: the effect is real, meaningful in certain populations, and most pronounced in those already carrying excess visceral fat.

The Mechanism

The beta-3 adrenergic receptor is the primary adrenergic receptor in visceral white adipose tissue and brown adipose tissue in adults. When noradrenaline — released from sympathetic nerve endings during fasting, exercise, or cold exposure — binds the receptor, it activates a Gs-protein66 Gs-protein
A stimulatory G-protein that activates adenylyl cyclase, the enzyme that produces cAMP from ATP signaling cascade. This increases intracellular cAMP77 cAMP
Cyclic AMP — the second messenger that activates protein kinase A, which in turn phosphorylates hormone-sensitive lipase, the rate-limiting enzyme for triglyceride breakdown in fat cells, activating hormone-sensitive lipase and driving lipolysis. In thermogenic (brown and beige) adipocytes, the same pathway activates UCP1 (uncoupling protein 1)88 UCP1 (uncoupling protein 1)
A mitochondrial protein that dissipates the proton gradient as heat rather than generating ATP — the core molecular mechanism of adaptive thermogenesis, generating heat.

The Trp64→Arg substitution occurs in the first intracellular loop, a region critical for receptor-G-protein coupling efficiency. The structural change reduces coupling fidelity, meaning the receptor produces a weaker cAMP signal for the same amount of hormonal stimulation. In practical terms: the fat-burning signal is intact but running at diminished amplitude. Adipose tissue from Arg64 carriers shows impaired catecholamine-stimulated lipolysis, reduced free-fatty-acid release, and attenuated thermogenic responses. In brown adipocytes specifically, the C allele significantly decreases the lipolysis rate.

The Evidence

Meta-analysis of BMI effects: The largest analysis to date, a meta-analysis of 97 studies involving 44,833 individuals99 meta-analysis of 97 studies involving 44,833 individuals
Kurokawa N et al. The ADRB3 Trp64Arg variant and BMI: a meta-analysis of 44,833 individuals. Int J Obes, 2008, found Arg64 allele carriers had 0.24 kg/m² higher BMI overall (p = 0.0002). The effect was strongly ethnicity-dependent: East Asians showed a significant +0.31 kg/m² association (p = 0.001), while Europeans showed a non-significant +0.08 kg/m² effect (p = 0.36). This ethnic specificity likely reflects differences in background adipose biology, lifestyle environment, and population history.

Adipokines and lipids: A comprehensive meta-analysis of 121 studies (54,059 subjects)1010 meta-analysis of 121 studies (54,059 subjects)
Luo Z et al. The Trp64Arg polymorphism in β3 adrenergic receptor (ADRB3) gene is associated with adipokines and plasma lipids: a systematic review, meta-analysis, and meta-regression. Lipids Health Dis, 2020 found that C allele carriers had significantly higher leptin, lower adiponectin, higher triglycerides, higher total cholesterol, and lower HDL-C. Effects were most pronounced in obese Asian women, suggesting that excess visceral fat amplifies the receptor's functional deficiency.

Type 2 diabetes: A systematic review and meta-analysis of 17 studies (4,864 T2D cases, 8,779 controls)1111 systematic review and meta-analysis of 17 studies (4,864 T2D cases, 8,779 controls)
Wang Q et al. Association of β3-adrenergic receptor rs4994 polymorphisms with the risk of type 2 diabetes: A systematic review and meta-analysis. Diabetes Res Clin Pract, 2017 found significant T2D risk increase in Asians across all genetic models (OR 1.11–1.78), with no significant effect in non-Asians.

Visceral fat during weight loss: In a study of 24 obese postmenopausal women1212 study of 24 obese postmenopausal women
Tchernof A et al. Impaired capacity to lose visceral adipose tissue during weight reduction in obese postmenopausal women with the Trp64Arg beta3-adrenoceptor gene variant. Diabetes, 2000, Trp64Arg carriers lost 43% less visceral adipose tissue during caloric restriction than non-carriers (−46 vs −81 cm², p = 0.05), despite similar total weight loss. Their cholesterol-to-HDL ratio also improved less (−0.18 vs −0.72, p = 0.04).

Japan Diabetes Prevention Program: In a lifestyle intervention study of 112 people with impaired glucose tolerance, non-carriers achieved significantly greater weight loss and HDL-C improvement1313 non-carriers achieved significantly greater weight loss and HDL-C improvement
Ohara M et al. Effects of lifestyle intervention on weight and metabolic parameters in patients with impaired glucose tolerance related to beta-3 adrenergic receptor gene polymorphism Trp64Arg. World J Diabetes, 2016 than Arg64 carriers in the intensive intervention group — suggesting the variant attenuates the benefit of standard lifestyle programs.

Practical Actions

The clinical picture for Arg64 carriers is one of reduced responsiveness to catecholamine-driven fat mobilization. The receptor still functions — it's not absent — but its signaling efficiency is diminished. This translates to blunted lipolytic response during fasting and exercise, impaired visceral fat loss during caloric restriction, and an adverse lipid profile that responds less briskly to lifestyle intervention.

Because the receptor still responds to agonist stimulation (just at lower amplitude), strategies that maximize sympathetic drive to adipose tissue can partly compensate. High-intensity interval training produces stronger catecholamine surges than continuous moderate exercise, providing a stronger stimulus to a receptor running at diminished gain. Omega-3 fatty acids (EPA and DHA) have been shown to increase ADRB3 expression in adipose tissue, providing a nutrigenomic avenue to partially restore receptor availability. Dietary protein higher than standard recommendations modestly increases sympathetic nervous system activity and thermogenesis.

Interactions

ADRB3 Trp64Arg has a documented interaction with rs1800592 (UCP1 −3826A>G). Both genes affect thermogenesis in adipose tissue through different mechanisms — ADRB3 at the receptor/signaling level, UCP1 at the mitochondrial uncoupling level. A study of 1,576 Brazilian T2DM patients found that carrying at least three minor alleles across both polymorphisms (rather than just one or two) was associated with protection against overweight/obesity (OR 0.288, p = 0.007) and higher HDL-C — suggesting a complex non-additive relationship between these two thermogenic pathway components. A Finnish study in diabetic and non-diabetic controls also found a synergistic effect on long-term body weight change.

A secondary interaction exists with rs1042714 (ADRB2 Gln27Glu). Both adrenergic receptor variants affect catecholamine-mediated adipose function through overlapping but distinct tissue distributions and signaling mechanisms. Studies examining both together show individual effects on fat mass, but direct statistical interaction evidence remains limited.

Nutrient Interactions

eicosapentaenoic acid (EPA) increased_need
docosahexaenoic acid (DHA) increased_need

Genotype Interpretations

What each possible genotype means for this variant.

AA Standard Fat Mobilization Normal

Normal beta-3 receptor function with efficient catecholamine-driven fat mobilization

You carry two copies of the A allele (Trp/Trp genotype) — the reference form of the beta-3 adrenergic receptor. Your ADRB3 protein has the standard tryptophan at position 64, maintaining normal first intracellular loop conformation and efficient G-protein coupling. This means your adipose tissue responds normally to catecholamine stimulation with full-amplitude cAMP production, lipolysis, and thermogenic signaling.

Approximately 81% of people of European descent share this genotype. In East Asian populations it is less common (around 64–68%), where the Arg64 allele is more frequent. Your standard receptor function means you do not carry the increased visceral fat retention or blunted lifestyle response associated with the risk variant.

AC Reduced Fat Mobilization Reduced

One Arg64 allele — moderately reduced catecholamine-stimulated lipolysis with impaired visceral fat response

As a heterozygote, your adipose tissue contains a mix of wild-type and Arg64 receptors. Cell studies demonstrate that the Arg64 variant produces approximately 70% less cAMP in response to beta-3 agonist stimulation. With one copy of each allele, your net signaling capacity lies between wild-type and Arg/Arg homozygotes.

The adipokine meta-analysis (Luo et al. 2020, 54,059 subjects) found that C allele carriers show higher leptin, lower adiponectin, elevated triglycerides, and lower HDL-C compared to AA individuals, though effect sizes were modest and most significant in obese Asian women.

The Japan Diabetes Prevention Program found that Arg64 carriers who underwent intensive lifestyle intervention achieved less weight loss and smaller HDL-C gains than wild-type individuals, suggesting the receptor variant attenuates standard intervention benefit even at one copy.

The risk of type 2 diabetes is increased primarily in Asian populations carrying this genotype (OR ~1.3 in Asians); evidence in European heterozygotes is less consistent.

CC Significantly Impaired Fat Mobilization Decreased

Homozygous Arg64 — substantially reduced catecholamine-stimulated lipolysis with elevated metabolic risk

In Arg/Arg homozygotes, essentially all beta-3 receptors in adipose tissue carry the coupling-deficient variant. The downstream consequences include: substantially reduced catecholamine-stimulated lipolysis, impaired visceral fat mobilization during caloric restriction, blunted thermogenesis in brown/beige adipocytes, and a persistently adverse lipid profile (higher leptin, lower adiponectin, elevated triglycerides, lower HDL-C).

The meta-analysis by Luo et al. 2020 (121 studies, 54,059 subjects) found the most pronounced metabolic effects in obese CC carriers, suggesting the combination of obesity and this genotype creates a synergistic metabolic burden. Studies using diet interventions found that Arg64 carriers consistently achieved less weight loss and smaller lipid improvements than non-carriers, and the Japan Diabetes Prevention Program lifestyle study found reduced benefit from intensive intervention in carriers.

The risk of type 2 diabetes in Asian CC carriers is substantially elevated (OR 1.76 in the recessive model in the T2D meta-analysis). Evidence in European CC carriers is less robust due to the low genotype frequency.

The receptor still responds to beta-3 agonists — it is not absent — but operates at significantly reduced gain. Strategies that maximize sympathetic tone in adipose tissue and support receptor expression can partially mitigate the deficit.